All the news

People with decompensated cirrhosis should be prioritised for COVID-19 vaccination and immunosuppressive treatment after a liver transplant should not be a barrier to vaccination, an international panel of liver experts has concluded. Their review ...

To eliminate hepatitis C in people with HIV in Scotland, healthcare providers will need to reach people not on HIV treatment and step up testing for hepatitis C in people ...

Public-sector hepatitis C treatment programmes have cured tens of thousands of people in lower- and lower-middle-income countries with the aid of low-cost direct-acting antivirals and diagnostics, a simplified approach to treatment and large-scale ...

Semaglutide, a medication approved to treat type 2 diabetes, increased the likelihood of improvement in non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis, researchers reported at the AASLD virtual Liver Meeting. What's more, ...

Twenty-four weeks of treatment with lanifibranor, a drug designed to treat NASH, improved liver fibrosis in 42% of people treated in a phase 2b clinical trial, Professor Sven Francque of Antwerp ...

Efruxifermin reduced liver fat and improved liver inflammation and fibrosis in the majority of people with NASH who received it in a phase 2a trial but nausea and vomiting led 10% of ...

Hepatitis C treatment in prisons can result in a high cure rate but people released from prison during treatment are less likely to be cured due to challenges in medication supply, continuity ...

Around 2.5 million people with hepatitis B in sub-Saharan Africa already have cirrhosis and need immediate antiviral treatment, a systematic review of published studies reports this month in the journal Liver International. Approximately ...

Around 1.1 million deaths were caused by viral hepatitis worldwide in 2019 and deaths due to hepatitis C are still rising despite the availability of direct-acting antiviral treatment, according to analyses of ...

Many people who take nucleoside/nucleotide antivirals for chronic hepatitis B can safely discontinue treatment, although this usually does not lead to a cure, researchers reported last week at the AASLD virtual Liver Meeting. Nucleoside/nucleotide analogues such ...